Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,996 shares of the biopharmaceutical company’s stock after selling 2,544 shares during the quarter. Pacer Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,107,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Cornerstone Wealth Group LLC grew its stake in Regeneron Pharmaceuticals by 3.7% during the fourth quarter. Cornerstone Wealth Group LLC now owns 3,865 shares of the biopharmaceutical company’s stock worth $2,753,000 after buying an additional 137 shares during the period. KBC Group NV boosted its position in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares during the period. Blue Trust Inc. increased its holdings in Regeneron Pharmaceuticals by 39.8% in the 4th quarter. Blue Trust Inc. now owns 724 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 206 shares in the last quarter. Strategic Investment Advisors MI raised its position in Regeneron Pharmaceuticals by 8.8% in the fourth quarter. Strategic Investment Advisors MI now owns 385 shares of the biopharmaceutical company’s stock valued at $275,000 after purchasing an additional 31 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 22.9% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,547 shares of the biopharmaceutical company’s stock worth $1,814,000 after purchasing an additional 474 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on REGN shares. Oppenheimer reduced their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Stock Up 0.2 %

REGN stock opened at $686.33 on Wednesday. The stock has a market cap of $75.42 billion, a PE ratio of 16.98, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The firm’s 50-day simple moving average is $725.65 and its 200 day simple moving average is $933.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.